# The Impact of Global Drug Policy on Women



# The Impact of Global Drug Policy on Women: Shifting the Needle

# **EDITED BY**

# **JULIA BUXTON**

University of Manchester, UK

# **GIAVANA MARGO**

Open Society Foundations, USA

# LONA BURGER

Action Canada for Sexual Health and Rights, Canada



Emerald Publishing Limited Howard House, Wagon Lane, Bingley BD16 1WA, UK

First edition 2021



Copyright © 2021 Julia Buxton, Giavana Margo, Lona Burger for the editorial matter and selection and © 2021 authors for their respective chapters. Published by Emerald Publishing Limited. These works are published under the Creative Commons Attribution (CC BY 4.0) licence. Anyone may reproduce, distribute, translate and create derivative works of these works (for both commercial and non-commercial purposes), subject to full attribution to the original publication and authors. The full terms of this licence may be seen at http://creativecommons.org/licences/by/4.0/legalcode

#### Reprints and permissions service

Contact: permissions@emeraldinsight.com

No part of this book may be reproduced, stored in a retrieval system, transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without either the prior written permission of the publisher or a licence permitting restricted copying issued in the UK by The Copyright Licensing Agency and in the USA by The Copyright Clearance Center. Any opinions expressed in the chapters are those of the authors. Whilst Emerald makes every effort to ensure the quality and accuracy of its content, Emerald makes no representation implied or otherwise, as to the chapters' suitability and application and disclaims any warranties, express or implied, to their use.

#### **British Library Cataloguing in Publication Data**

A catalogue record for this book is available from the British Library

ISBN: 978-1-83982-885-0 (Print) ISBN: 978-1-83982-882-9 (Online) ISBN: 978-1-83982-884-3 (Epub)



The ebook edition of this title is Open Access and is freely available to read online.



ISOQAR certified Management System, awarded to Emerald for adherence to Environmental standard ISO 14001:2004.

Certificate Number 1985 ISO 14001



# **Contents**

List of Figures and Tables	ix
About the Contributors	xi
Introduction Julia Buxton, Lona Lauridsen Burger and Giavana Margo	1
Chapter 1 International Drug Policy in Context Julia Buxton and Lona Burger	9
Chapter 2 Gendering Drug Policy Fiona Macaulay	23
Chapter 3 Women and the Politics of Pleasure in Critical Drug Studies Ingrid Walker	33
Chapter 4 Fiona's Story Fiona Gilbertson	41
Health, Care and Treatment: Stigma, Gaps and Vulnerabilities	
Chapter 5 Nexus of Risk: The Co-occurring Problems of Gender-based Violence, HIV and Drug Use Among Women and Adolescent Girls Claudia Stoicescu, Ariel Richer and Louisa Gilbert	49
Chapter 6 Risk Behaviours Among Older Women Who Use Drugs	• •
April Shaw	59
Chapter 7 Women Who Use Drugs and Mental Health Zsuzsa Kaló	67

Chapter 8 Access Barriers to Health Services for Women Who Use Drugs in Eastern Europe and Central Asia	
Daria Matyushina-Ocheret	75
Chapter 9 Suzanne's Story Suzanne Sharkey	85
Chapter 10 Sex Work, Justice and Decriminalisation: Beyond a Politics of Recognition in Promoting a Social Justice Response to Women at the Margins	
Anastacia Ryan	91
Criminal Justice, Injustice and 'Criminality'	
Chapter 11 Women Incarcerated for Drug-related Offences: A Latin American Perspective	
Corina Giacomello and Coletta A. Youngers	103
Chapter 12 Policing and Sentencing Practices in Russia and their Impacts on Women Who Use Drugs	
Giavana Margo	113
Chapter 13 Women, Drug Policy and the Kenyan Prison System Mary C. K. Chepkonga	123
Chapter 14 Drug Policy and Women Prisoners in Southeast Asia Chontit Chuenurah and Ukrit Sornprohm	131
Chapter 15 The Increase in Women Who Use Drugs in Zimbabwe Wilson Box	141
Chapter 16 Women as Actors in the Drug Economy  Julia Buxton	147
Chapter 17 Women's Involvement in Organised Crime and Drug Trafficking: A Comparative Analysis of the Sinaloa and	
Yamaguchi-gumi Organisations Cecilia Farfán Méndez	159
Chapter 18 From the Colombian Coca Fields: Peasant Women Amid the War on Drugs	
Isabel Pereira and Lucía Ramírez	169

Chapter 19 'Las Empoderadas' Women Coca Growers Building Territorial Peace	
Ingrid Marcela Muñoz Quesada	179
Chapter 20 Unseen and Unheard: The Women in Duterte's War on Drugs	
Kristine Mendoza	183
Best Practice, Mobilisation and Reform Agendas: Towards Narco Feminism	
Chapter 21 Happy's Story	
Happy Assan	191
Chapter 22 Women Surviving the Overdose Crisis in New York City: A Glimpse into the Unique Overdose Risks and Prevention Strategies for Pregnant Women Bethany Medley	195
	193
Chapter 23 Patterns of Recreational Drug Use and Harm Reduction Strategies among Women at Music Festivals: The Case of Hungary and Poland	
Iga Kender-Jeziorska	201
Chapter 24 Queer Feminine Identities and the War on Drugs  Ailish Brennan	213
Chapter 25 Best Practices in Reaching 'Hidden' Populations	
and Harm Reduction Service Provision Fatma Jeneby, Abdalla Badrus, Husein Abdalla Taib, Aggrey Alluso, Luke Okunya Odiemo and Habil Otanga	217
Chapter 26 A Mother's Story Rose	229
Chapter 27 Drug Users as Stakeholders in Drug Policy: Questions of Legitimacy and the Silencing of the Happy Drug User Anna Ross	237
Chapter 28 Improving Drug Policy Metrics and Advancements in Measuring Gender-based Drug Policy Outcomes Marie Nougier	247

Index

# Impacts of Global Drug Policy Enforcement Chapter 29 Towards an Abolitionist Drug Policy Reform Imani Robinson 259 Chapter 30 Women Who Use Drugs: Resistance and Rebellion Judy Chang 271 References 287

325

Shifting the Needle: A Gendered Perspective on the

# **List of Figures and Tables**

Figures		
Chapter 18	3	
Fig. 1.	Coca Crops, Aerial Fumigation, and Manual Eradication in Putumayo (1999–2016)	175
Chapter 23	3	
Fig. 1. Fig. 2.	The Substances Consumed by Women during a Festival ( $N$ =510) The Number of Different Substances Used by Women at a Festival ( $N$ =510)	204 210
Tables		
Chapter 11	t.	
Table 1.	Increase in Female Prison Population in Latin America	105
Chapter 23	3	
Table 1.	The Prevalence of Substance Use among Female Festivalgoers	203
Table 2. Table 3.	Patterns of Drug Use among Women at Festivals Substances Used During a Festival by Women Who	209
	Tend to Mix Drugs	210



# **About the Contributors**

**Aggrey Alluso** is a social sciences graduate with over 15 years' experience of work in advocacy for social and legal reforms and grant making. His focus is to create an enabling ecosystem for sustained (social, political and legal) reforms towards social justice for marginalised groups, using intersectional lenses and rights-based approaches.

**Happy Assan** is an activist and outreach worker for people who use drugs and those living with HIV. She serves as Executive Director of the Tanzania Network for People who Use Drugs and founded SALVAGE, an organisation aimed at providing services and support to women who use drugs and their children. Her work is motivated by her lived experience of drug use and related stigma and discrimination.

Abdalla Badrus is a Harm Reduction Programme Manager at MEWA (Muslim Education and Welfare Association), a local NGO in Mombasa, Kenya. He has over 20 years' experience working with People Who Use Drugs (PWUD). He is Co-founder of Muslim Education and Welfare Association (MEWA) Drug Treatment Centre and Harm Reduction Programmes and a Vice Chair of Kenya Harm Reduction Network. He has a higher Diploma in Counselling Studies.

Wilson Box is an activist, practitioner and Projects Executive Director for Zimbabwe Civil Liberties and Drug Network. He is a fellow of the Open Society Foundations and has undertaken courses on human rights and drug policy reform at the Central European University in Budapest, Hungary, and in Drug Policy Reform, Global Health and Diplomacy at the Graduate Institute of the University of Geneva.

**Ailish Brennan** is a youth activist working on drug policy, and LGBTQ+ issues, especially focussing on the intersection of these topics. She has completed a Bachelor of Arts degree in Politics, International Relations and Economics at University College Dublin, and is currently the Executive Director of *Youth RISE*.

**Judy Chang** is the Executive Director of the International Network of People Who Use Drugs and has been a drug user, drug policy and harm reduction advocate since 2015. Additionally, she has a combined 10-year experience in the field

of HIV, community health and gender inequality spanning research, advocacy and programming. As a woman who uses drugs, she brings decades of lived experience and personal dedication to the role. She has worked across India, China and Thailand. She holds a Masters in International Development and a Bachelor of Arts in Writing and Contemporary Cultures.

Mary C. K. Chepkonga, Rtd, SACP, HSC, OGW, is a Consultant who retired as a Senior Assistant Commissioner of Prisons. She holds a BSc (Hons) in Health Systems Management from the University of Manchester (UK) and worked for 39 years with Kenya Prisons Service. Her main areas of competence and expertise are in drugs, HIV and AIDS, policy development and implementation, programme implementation and coordination, budgeting and work plan formulation, capacity building and donor liaison and fundraising.

**Chontit Chuenurah** has worked to promote gender-sensitive treatment of women prisoners and support the implementation of the UN Bangkok Rules in Southeast Asia during the past 10 years. As part of her work, she leads several research projects focusing on women's background and pathways to imprisonment.

**Cecilia Farfán Méndez** is the Head of Security Research Programmes at the Center for US–Mexican Studies at the University of California San Diego. She is an expert on organised crime and US–Mexico security cooperation. Her work has been published in Open Democracy, The Conversation and the *Journal of Illicit Economies and Development*.

**Corina Giacomello** is a researcher and consultant on gender, justice and drug policy. Her publications and research focus on women in prison, children with incarcerated parents, women who use drugs and compulsory treatment. Her work is based on empirical research and comparative law, with a focus on Latin America, specifically Mexico.

**Louisa Gilbert** is an Associate Professor at Columbia University School of Social Work and Co-director of the Social Intervention Group and Global Health Research Center of Central Asia. Her research has focussed on advancing syndemic interventions to address gender-based violence, HIV and substance misuse among women who use drugs.

**Fiona Gilbertson** has over 25 years of advocacy experience in HIV and sex work organisations mainly in policy development and lobbying. She founded Recovering Justice in 2013 believing that the fundamental way to tackle stigma and discrimination is through policy change. They seek peaceful solutions to the war on drugs.

**Fatma Jeneby** is a clinical anesthetist advocating for rights of people who use drugs in Kenya's Coastal Region. She has been working for the Muslim Education and Welfare Association for the past 13 years with vast experience on

designing and monitoring community response to health, harm reduction and rights services.

**Zsuzsa Kaló** is Assistant Professor in Psychology at the Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary. She is a linguist and a psychologist. Her primary research interests are female drug use and qualitative drug research methods.

**Iga Kender-Jeziorska** is a drug policy researcher and activist focussed on harm reduction policies and interventions in East-Central Europe. She serves as a Deputy Director of the Youth Organisations for Drug Action and a member of the core group of the Civil Society Forum on Drugs of the European Commission.

**Fiona Macaulay** is Senior Lecturer in the Department of Peace Studies and International Development at the University of Bradford. She previously worked at Amnesty International and the Universities of Oxford and London. Her research interests span gender, politics and policy, human rights and reform issues in the criminal justice system and security sector, in Brazil and Latin America.

**Daria Matyushina-Ocheret** is a public health expert with over 20 years of experience in harm reduction and drug policy. Originally from Russia, she led on community-based research and advocacy projects first in the region of Eastern Europe and Central Asia and more recently on the international level.

**Bethany Medley** is a current Ph.D. student at Columbia University School of Social Work. She identifies as a person with lived experience of intravenous heroin use and as an advocate for people who use drugs. Her research interests include community-based participatory research with women of reproductive age who use drugs.

**Kristine Mendoza** is a Filipino Lawyer working for the rights of People Who Use Drugs, People Living with HIV and LGBTIQs. She is a founding member of StreetLawPH, an organisation of lawyers which provides access to justice services for People Who Use Drugs in the Philippines. She studied Political Science and earned her Juris Doctor degree from the University of the Philippines Diliman. She became a member of the Integrated Bar of the Philippines in 2016.

Ingrid Marcela Muñoz Quesada holds a degree in Natural Sciences from the South Colombia University and is currently studying a Masters in Integral Management of Hydrographic Basins from the National University of La Plata, Argentina. Since 2008, she has accompanied social and campesina organisations in political and social work projects, and she continues to work towards Colombia's peace and reconciliation process.

Marie Nougier manages the communications/publications of the International Drug Policy Consortium (International Drug Policy Consortium) communications/

publications work, while engaging in networking, NGO capacity building and policy advocacy engagement. She helps coordinate a project on women, incarceration and drugs in Latin America and is a Core Group member of the EU Civil Society Forum on Drugs (CSFD) (Civil Society Forum on Drugs). She has an MA in international law, human rights and security.

**Luke Okunya Odiemo** is Senior Lecturer in the Department of Psychology at the University of Nairobi and a Practitioner in Psychometrics with the Centre for Cognitive Interventions. He has interest in psychological issues relating to community problems and how psychological assessment can be used to design interventions.

**Habil Otanga** is Lecturer in the Department of Psychology at the University of Nairobi.

**Isabel Pereira** holds a Political Science degree from University de Los Andes and a Masters degree in Development Studies, from IHEID, Switzerland. She focusses on the impact of drug policy on rural development, public health and armed conflict. She is currently the Research Coordinator for the Drug Policy area at Dejusticia.

**Lucía Ramírez** is an attorney specialised in Constitutional Law from Colombia's Universidad Nacional and has a Master's degree in Social Work from the University of Chicago. She has worked in research, teaching, litigation and advocacy on human rights. Currently, she is the Research Coordinator for migration at Dejusticia.

**Ariel Richer** is an NIH T32 Pre-Doctoral Fellow at the Columbia University School of Social Work working within the Social Intervention Group. She focusses on intimate partner violence prevention, drug and alcohol use and HIV/STI risk. She works collaboratively with Black, Indigenous, and Native communities. She is Co-founder and Director of Research and Advocacy of the Urban Indigenous Collective.

**Imani Robinson** is the Communications Strategist for Release, the United Kingdom's centre of expertise on drugs and drugs law, and the current editor of TalkingDrugs.org, one of the few multilingual online platforms dedicated to providing unique news and analysis on drug policy, harm reduction and related issues around the world.

**Rose** supports Anyone's Child: Families for Safer Drug Control. Drugs ruined the lives of two of her three sons, then heroin killed them. Her youngest son died when waiting for treatment, while people with him delayed calling 999. Her second son, in recovery, relapsed and died alone.

Anna Ross Anna Ross is a drug policy specialist and community engager who has written her PhD thesis on participation within Scottish drug policy formation. She has a long history of involvement with drug user communities and is a passionate advocate of the human rights underpinning drug policy reform.

Anastacia Ryan is a researcher, advocate and social entrepreneur in promoting the rights of marginalised women globally. Her belief in the need for leadership of marginalised communities led her to establish the sex worker-led project Umbrella Lane, which is now part of a larger project she founded, SISU, which empowers women and girls to build resilience through adversity.

**Suzanne Sharkey** has been advocaring and campaigning for drug policy reform since 2014. She is Vice-chair of Law Enforcement Action Partnership in the United Kingdom. As a woman in long term recovery from alcohol and other drugs, she knows only too well the inequalities women face and continues to fight these injustices.

**April Shaw** has almost two decades of experience conducting substance use research in the United Kingdom and Europe. She is currently undertaking a PhD at the University of Glasgow. Using creative qualitative methods, her research explores the concepts of agency and control experienced by mid-life and older women in recovery from illicit drug use.

**Ukrit Sornprohm** is Project Manager at the Thailand Institute of Justice where he plans, manages and executes research and policy advocacy projects on crime prevention and criminal justice matters including transnational crime and gender equality. He also serves as a special lecturer at several universities in Thailand.

**Claudia Stoicescu** is a Research Associate at Oxford University's Centre for Criminology and Department of Social Policy and Intervention and a Visiting Scholar at Atma Jaya University's HIV/AIDS Research Centre. Her research uses participatory approaches to explore the intersections of HIV, drug use and genderbased violence among marginalised women.

**Husein Abdalla Taib** is a social worker who has, for the last 20 years, been working with the Muslim Education & Welfare Association – working with people who use drugs at the Coastal Region of Kenya. He is currently the Head of Advocacy for Health and Harm Reduction Services.

**Ingrid Walker** is Associate Professor of American Studies at the University of Washington, Tacoma. She researches the relationships between drugs, users and social perceptions that inform policy. Her publications include *High: Drugs, Desire, and a Nation of Users*, and articles, chapters and a TED talk about drug research, normalisation and pleasure.

**Coletta A. Youngers** is a Senior Fellow at the Washington Office on Latin America and a Senior Associate with the International Drug Policy Consortium (IDPC). She is an expert on human rights and drug policy in Latin America, and coordinates a project on women, drug policy and incarceration in the Americas.



# Introduction

Julia Buxton, Lona Lauridsen Burger and Giavana Margo

This edited collection brings together contributors from around the world in an exploration of women, drugs and the impact of drug policy enforcement on women. The dramatic expansion in the availability and use of psychoactive substances over recent decades has transformed the way women interact with illicit drug markets. Either directly as cultivators, manufacturers, distributors and users of mind and mood-altering substances or indirectly as the partner, parent or carer of people involved in drug markets, an ever-expanding number of women are engaging with plant-based, chemical and diverted pharmaceutical substances. In turn, this means that more women are being caught up in drug policy enforcement.

International drug control is now over a century old. It is one of the earliest models of 'welfare internationalism' (Midgley, 1997), drawing nation states together in the common cause of protecting their populations from potentially harmful substances. Over the decades following the foundational 1909 meeting in Shanghai, vast, international and national level bureaucracies have evolved to uphold and enforce the prohibition of a select range of substances. Scientific advance has shown that the classification of these 'narcotics' does not correlate with the physical and mental health dangers assumed. Rather than reflecting potential harms, the schedule of controlled drugs is informed by a perceived threat to the family, order, hierarchy and conformity posed by the individuals, cultures and social groups that use them (Reinarman & Levine, 1997). The use of drugs by women, and/or their wider involvement in the illicit trade, is acutely transgressive. It runs against ascribed notions of femininity and motherhood across cultures and societies and, as a result, women are disproportionately punished, stigmatised and vilified. From this perspective, drug policy serves to reinforce existing systems and structures of gendered power and exclusion.

An estimated US\$100 billion per year is spent in pursuit of the goal of a 'drug-free world'. The bulk of these revenues are spent on law enforcement activities to counter a trade with an annual turnover of US\$330 billion per year,

The Impact of Global Drug Policy on Women: Shifting the Needle, 1–8 Copyright © 2021 by Julia Buxton, Lona Lauridsen Burger and Giavana Margo These works are published under the Creative Commons Attribution (CC BY 4.0) licence. Anyone may reproduce, distribute, translate and create derivative works of these works (for both commercial and non-commercial purposes), subject to full attribution to the original publication and authors. The full terms of this licence may be seen at http://creativecommons.org/licences/by/4.0/legalcode

doi:10.1108/978-1-83982-882-920200001

while prevention and treatment are neglected. As discussed in the first chapter, whatever the financial outlays, prohibition is unachievable. Not only is it an unrealistic policy goal, the strategy of criminalising all forms of engagement with controlled drugs as set out in the 1961 United Nations Single Convention on Narcotic Drugs is counterproductive. It has generated a massive and lucrative illicit economy, one in which seizures of illegal drugs drive up prices, incentivising participation in the illicit trade. Eradication and interception dissipate drug market activities, extending manufacture, trafficking and use into new territories and geographical spaces. Enforcement of criminalisation leads to violations of human rights, corrupts state actors, corrodes state institutions and generates new forms of social and political violence. In criminalising personal and private behaviours, drug policy perpetuates stigma and generates multiple risks to individual and public health. In sum, criminalisation causes infinitely more harm than good.

The negative impacts and outcomes of drug policy implementation are neglected and inadequately captured by drug control institutions. Remarkably, and unlike any other area of public policy, the persistence of current drug policy approaches is justified through reference to unmeasured protection of 'health and wellbeing' and the promotion of higher moral purpose. The reality is that a greater variety of cheaper and purer drugs are available to an ever-expanding global market of consumers (UNODC, 2019a). From local to international level, we are not protected from the assumed dangers of drugs. Rather, drug policy galvanises drug market innovation and adaptation, while criminalisation exposes all of us to new and multiple forms of risk and vulnerability.

This collection is a catalogue of the routine and multiple injustices that women experience as a result of a policy that is not fit for purpose. The costs and impacts of drug policy enforcement are widely recognised as unequally distributed. Drug policy policing and criminal justice processes have been extensively documented as racist (Alexander, 2012; Hart, 2014; Koram, 2019) and targeted towards a variety of 'deviant' groups (Musto, 1999). Enforcement practices reinforce marginalisation, vulnerability and structural inequalities, with the most exploited countries and communities carrying the heaviest financial and social costs of a flawed policy. Until very recently, little attention was paid to the impacts of drug policy and enforcement on women. Men are the main actors in both the illicit trade and in its prevention and policing, as well as treatment services. In emerging into this heavily masculinised space, women are experiencing new forms of misogyny, exclusion, violence and sexual violence perpetrated by both non-state and state actors, informal and formal institutions. This layers onto other existing practices of gender discrimination and exclusion.

This book aims to advance new ground. Firstly, it explicitly focusses on women, breaking with a long tradition of scholarship, policy and policy analysis that has been gender blind (Campbell & Herzberg, 2017; Maher & Hudson, 2007). Secondly, in working internationally, it seeks to expand the small corpus of existing analysis of women and the drug trade, which has been overwhelmingly dominated by North American, and to a lesser extent, West European scholarship. Prohibition and the criminalisation of drugs is international and structured through a series of United Nations conventions. Chapters in this collection expand the

geographical boundaries of engagement with the issue of women, drugs and drug policy, reflecting universalised and wholly negative commonalities of experience. The book also seeks to be innovative in bringing together contributors who are not only from different parts of the world but also a diversity of backgrounds and experiences related to drugs and drug policy. Practitioners, professionals, academics and those with lived experience are brought together in this collection with the aim of overcoming traditional silos, to decolonise approaches and to provide an opportunity to hear from those who are usually neglected or distilled into codes and numbers in scholarship. Alongside chapters presented in a traditional academic format, we integrate policy-based commentaries and 'voices' the verbatim accounts of women with direct experience of the many failures of drug policies. In a rare contribution to drug policy debates, this book also welcomed auto-ethnographic chapters. As outlined by Walker in Chapter 3, this situates 'the individual epistemologically in the political and cultural through the personal'. Following Ettorre (2017a), auto-ethnography is intended to transform personal experience into 'narrative representations of political responsibility' (p. 359). It serves here as an active demonstration of the personal as political.

This approach was hugely valuable. It enabled us as a collective to identify major gaps in research and policy, to engage with a breadth of experiences, to better understand the international dimensions of women's exposure to militarised drug 'wars' and policing, and to learn from each other. The most salient takeaway for the editorial team was the emotions, vulnerabilities and tragedies opened up and exposed by this endeavour, the value of mutual support whatever our backgrounds and nationalities, and the enormous resilience and strength of women demanding defence and promotion of their fundamental rights and campaigning for change to a policy that routinely violates and erodes their human rights.

# A Note on Terminology

Gender-based discrimination permeates society and the policy-making process. As discussed by Macaulay in Chapter 2, we understand gender relations as a socially constructed set of expectations around men and women's roles, behaviours, practices and symbols in any given society. Gender norms are also relational: femininities and masculinities are constructed in relation to their own variants ('good women' and 'bad women') as well as in relation to one another (men who are seen as 'feminine' are seen as failed). Gender norms are also the product of patriarchal and unequal societies, which regard women as essentially inferior. As outlined by Schleifer and Pol (2017, p. 254), gendered identities 'affirm and reestablish a higher level of privilege for those categorized as male with respect to access to resources, employment and personal autonomy'.

Our approach in this book is to understand biological sex as more complex than assumed in the binary delineation of female and male, and we acknowledge that for some individuals, birth-assigned and self-identified gender are in conflict. Delineating who is, and who is not, a 'woman' is not our preoccupation. Our concern is the experience of intersecting patterns of exclusion and discrimination on the basis of assigned or assumed femaleness and how these are reinforced by the disciplining tool of drug policy. We draw attention to the inadequacy of monitoring, reporting and evaluation systems and the failure of nation states to fulfil their obligations to women, defined inclusively, as set out in international human rights treaties including the UN Charter, International Covenant on Civil and Political Rights and the International Covenant on Economic, Social and Cultural Rights. The 1979 Convention on the Elimination of All Forms of Discrimination against Women (CEDAW) defines the right of women to be free from discrimination. It establishes core principles to protect this right and provides an agenda for states to achieve equality between men and women. This includes by ensuring women's equal access to and equal opportunities in public life, education, health and employment. This book demonstrates that in the enforcement of drug policy and through the persistence of criminalisation-based drug policy strategies, states are reneging on these obligations, including in relation to the reproductive rights of women as set out in CEDAW (see also Schleifer & Pol, 2017).

At the same time, we acknowledge that the experience of women cannot be homogenised. Discrimination on the basis of race, class, age, religion, sexual preference, gender identity and ethnicity create intersecting vulnerabilities, disadvantage and denial of human rights. We did not want to pursue an approach that can be conceived as tokenistic. Many of us have experience of the divisions and debates within each of these individual streams of exclusion, and it is not for us to determine who does and who does not speak for particular communities. We are of the view that this particular historical moment, a period of resurgent rightwing nativism and pushback against women's freedom and rights, requires a common platform. In particular, this is a call for feminist research and advocacy to grasp the salience of drug policy as a women's issue and for feminist and women's movements to engage with the urgency of drug policy reform.

Stepping from the disputes within feminism and around womanhood, we are aware that some readers may object to our use of the term 'drugs'. For some within the drug policy reform and drug policy abolition movement, perpetuating the terminology of 'drugs' distracts from the social and political construction of the risks associated with a range of naturally occurring plant-based substances and synthetics (see e.g. Nutt, King, & Phillips, 2010). Furthermore, these risks are overwhelmingly linked to criminalisation. As discussed in Chapter 1, criminalising the manufacture, cultivation, distribution, possession and use of drugs and enforcing this with punitive policing and legal processes prevents individuals from knowing the contents of substances they are consuming, it encourages cutting and diluting for profit, and it leads to dangerous consumption practices. In our use of the term 'drugs' in this collection, we refer to those substances that are scheduled in the system of controls and restrictions established in the UN international drug treaty conventions (see Jelsma & Hallam, 2014).

## **Structure of this Collection**

For those unfamiliar with drug policy, Chapter 1 by Julia Buxton and Lona Burger provides an overview of history and approaches. It discusses the norms and assumptions that have framed international strategy and national level policies by default. It is acknowledged that international drug policy may be at a turning point. The traditional consensus around criminalisation is fracturing, with over 30 countries and a significant number of individual states in the United States introducing some form of decriminalisation initiative over the last decade. While this is a positive step for drug policy reform, the changes to date relate largely to cannabis, have been subject to reversal by incoming governments, and they are implemented at the edges of a prevailing prohibition consensus. As such, we write about a prevailing drug policy paradigm, one that has failed to make any progress in the availability of controlled drugs, which continues to cause grave harm in enforcement impacts and which remains unacceptably gender blind in its evaluation and assessment of outcomes.

In Chapter 2, Fiona Macaulay steers discussion of drug policy towards consideration of how analysis can and should be gendered. Her contribution discusses existing structures of gendered inequalities and vulnerabilities of women, including in relation to health and security, and how these are exacerbated and reproduced by drug policy and criminalisation approaches. This frames subsequent contributions on the impact of drug policy policing and criminal justice processes and issues around health, ill health and women's access to treatment and services. While this collection is overwhelmingly focussed on the searing and disproportionate negativities of drug policy enforcement and criminalisation on women, Chapter 3 by Ingrid Walker addresses the issue of pleasure in research about women and drug use. Through the lens of critical drug studies, Walker explores women's drug use as a mechanism of rebellion, activism and self-exploration, which are emphasised as mechanisms for change in the concluding section of this book. Chapter 4 introduces Fiona's Story, an interview with Fiona Gilbertson of Recovering Justice. Following from Walker, this is a narrative of empowerment and mobilisation from the lived experience of exclusion. In what emerges as a common theme in the collection, Fiona's Story illustrates how gendered hierarchies are reproduced across social and organisational spheres, including within the recovery and drug policy reform community.

The section 'Health Care and Treatment: Stigma, Gaps and Vulnerabilities' drills down on the particular vulnerabilities of women, both as users of drugs and as experienced relationally as the partners of men who use drugs. The contributions in this section highlight unacceptable weaknesses in research, epidemiology and services for and in relation to women and the barriers women face in accessing appropriate care and treatment. Claudia Stoicescu, Ariel Richer and Louisa Gilbert address a 'nexus of risk' configured around gender-based violence, HIV and drug use; April Shaw analyses risk behaviour among older women who use drugs and Zsuzsa Kaló explores issues of pre-existing mental health conditions, trauma and post-traumatic stress disorder. Underscoring the universalised nature of the obstacles that women face, Daria Matyushina-Ocheret examines the barriers to health services faced by women in Eastern Europe and Central Asia. In the second of our 'Voices' contributions, Suzanne Sharkey relates a personal experience of struggle: to access appropriate and female centred provision in treatment, care and recovery. It is a compelling narrative, a journey that starts with her former career in the police service and which recounts the stigma, guilt and shame of

dependent use. These themes are echoed in the contribution by Anastacia Ryan. Using the case study of sex work, Ryan reminds us that legal change without an agenda of social justice is an inadequate mechanism for addressing structural inequalities and social marginalisation.

The section 'Criminal Justice, Injustice and "Criminality" turns attention to women's experience of enforcement and exposure to criminal justice system processes. To contextualise these trends, Julia Buxton provides an analysis of existing research on women's changing roles in drug supply activities. Corina Giacomello and Coletta A. Youngers explore the staggering rise in the incarceration of women for drug-related offences in Latin America. Their research draws attention to women's lack of access to justice in the region, the pressures that women face from male relatives and partners to engage in drug-related activities, and the circumstances of chronic vulnerability and poverty that renders the illegal drug trade a viable means for women to support vulnerable livelihoods. This latter aspect is further developed by Isabel Pereira and Lucía Ramírez in their discussion of women coca growers in Colombia. They highlight conditions of rural marginality and insecurity that renders engagement in coca cultivation a crucial livelihoods strategy. Ingrid Marcela Muñoz Quesada provides a profile of these women, trapped in a cycle of poverty, insecurity, insurgency and drug 'war' violence.

Discussions around disproportionate and punitive sentencing in penal processes relate back to earlier themes of patriarchy and cultural expectations of women, and the draconian nature of punishment for transgression. This is echoed by Giavana Margo in her analysis of policing and sentencing practices in Russia, and by Chontit Chuenurah and Ukrit Sornprohm in relation to drug policy and women prisoners in South East Asia. Drawing on diverse geographical experiences, all three chapters emphasise the failure of states to provide appropriate support, rehabilitation and services for female prisoners, the vulnerability of incarcerated women to institutionalised violence and the impacts of punitive sentencing on families and children.

Mary C. K. Chepkonga served as Deputy Commissioner for Kenya's Prisons Service. From a national perspective, she comments on the failure of states to adopt best practice recommendations for the protection and care of female prisoners, and the gap between declaratory statements and national commitments on prison standards and the institutionalised hostility to actual implementation. Wilson Box presents a snapshot of the rise in the numbers of women who use drugs in Zimbabwe. As with earlier chapters in this section, the contribution from this non-governmental organisation focusses our attention on police and border guards as complicit in women's drug-related activities and as perpetrators of violence and sexual violence against women who use or distribute controlled drugs. As discussed in Chapter 1, this abuse of institutional power and office underlines a core myth of drug policy: that there is a neat binary between the 'evil' drug trade and the 'good' state. Criminalisation corrupts state actors and corrodes state institutions. Rather than a black and white Manichean drug 'war' struggle, the reality in all of our countries is a dirty grey area where formal and informal blur. This links to our third Voices contribution from Kristine Mendoza. Working in the front line as a street lawyer in the Philippines, her narrative presents a damning indictment of the violence and rights abuses of President Rodrigo Duterte's drug 'war'.

While the collection focusses on women's exposure to crude and violent enforcement impacts and state neglect, we felt it necessary to include other considerations of women and the drug trade. Just as Walker provides a discussion on drug use and pleasure, Cecilia Farfán Méndez provides a fascinating analysis of women's involvement in organised crime and drug trafficking through a comparative analysis of Mexican and Japanese organisations.

The final section 'Best Practice, Mobilisation and Reform Agendas: Towards Narco Feminism' brings together academics and activists from diverse geographical contexts, all relating strategies of survival and politicisation. Two contrasting 'Voices' reflect the diversity of drug policy enforcement experiences that inform our demand for radical policy change. Happy narrates her experience of drug use, service denial and emergence as a drug policy reform activist in the narrow and dangerous space of advocacy work in Tanzania. Rose is British and retired and writes from her experience of grief. She narrates the tragedy of losing two sons in a protracted and unsuccessful struggle to get treatment and support for their drug dependence. In a theme that weaves across our collection, Rose talks of the stigma that prohibition has built around the use of drugs and the impacts that this has on families. In her story, Rose narrates the isolation created by cultures of silence and shame and discusses how the organisation Anyone's Child provided – for the first time – a community of shared experience: families grieving the unnecessary and tragic death of loved ones.

Bethany Medley, Fatma Jeneby and Iga Kender-Jeziorska pull us across the globe, with insights on harm reduction, self-organisation and strategies for reaching women made vulnerable by the criminalisation of drugs in the United States, Central Europe and East Africa. Medley's chapter examines overdose prevention strategies among pregnant women in New York City, while Jeneby and colleagues discuss best practice in outreach and medical services for female drug users in Kenya. Kender-Jeziorska analyses recreational drug use among women at music festivals in Hungary and Poland, with her chapter presenting strategies for reducing associated harm. Ailish Brennan draws from her experience as a transgender woman who uses drugs to discuss the differential and compounding impacts of drug policy enforcement on sexual and gender minority groups. Using the term 'womxn' as explicitly inclusive of non-cisgender women, Brennan highlights the overlapping exclusions which further complicate queer women's access to drug-related services.

As discussed in Chapter 1, it is only very recently that international drug control institutions have acknowledged the importance of a gender perspective and gender sensitivity in drug policy. It was only in 2016 that the UN General Assembly Special Session on Drugs (UNGASS) saw Drugs saw member states commit to mainstream: 'a gender perspective into and ensure the involvement of women in all stages of the development, implementation, monitoring and evaluation of drug policies and programmes' and to recognise the specific needs, vulnerabilities and circumstances of women and girls (Schleifer & Pol, 2017). But as with so many aspects of high-level commitments and the reality of actual implementation, little has been achieved in practice. Marie Nougier addresses a key gap: information. Her contribution provides a valuable analysis of how drug policy metrics can be gendered so that the performance indicators of national and international drug policy institutions can better engage with the impacts of implementation on

women. Through the lens of national-level experience, Anna L. Ross outlines the challenges that women and women who use drugs face in being recognised and accepted as stakeholders in drug policy. Anna brings auto-ethnography into her account, recounting with welcome frankness how self-identification as a woman who uses drugs can close many policy doors. Silencing and excluding those who engage with illegal drug markets precludes the uptake of evidence from people with lived experience, pushing them to the margins of drug debates. Imani Robinson and Judy Chang present two powerful calls for action, rebellion and mobilisation. Like Anna, both integrate personal experience with scholarship and evidence-based research to present compelling argumentation – not only for drug policy change, but for social justice, respect and personal autonomy.

### A Few Words of Thanks

We present a diverse and eclectic mix of chapters, stories and insights, in turn reflecting the diversity of women's experiences and interactions with drugs and drug policy across the globe. Contributors were initially brought together through a series of workshops and organisational platforms unified by the common themes of providing necessary visibility to the experience of women and of the urgency of change to international and our own national-level drug policies.

We would like to take the opportunity to thank colleagues who supported and participated in these events and to acknowledge the importance of their research, advocacy and activism in driving increased attention to the gross injustices and vulnerabilities resulting from the criminalisation of drugs and from drug policy enforcement activities. We thank the Global Drug Policy Programme of the Open Society Foundations and our grant manager Matt Wilson for the financial support that enabled us to develop this project and Mama Diene who assisted us in convening our regional workshop in Ghana. The organisational and administrative assistance of the Global Policy Academy led by Bernhard Knoll-Tudor at Central European University in Budapest was invaluable in keeping our activities and events on track with thanks to Livia, Nora and Tanja. We express our immense gratitude to OSF for allowing us to redirect funds that were planned for (pre-COVID) conference activities to Open Access of this publication, and to the International Network of People Who Use Drugs (INPUD) and the Center for US-Mexican Studies, University of California San Diego for the additional financial support that got us over the line for full Open Access publication. Our sincere gratitude to Judy Chang at INPUD and Professor Rafael Fernández de Castro at UCSD. The editors met while variously working and studying at Central European University in Budapest, where in his capacity as founding Dean of the School of Public Policy, Professor Wolfgang Reinicke offered unending encouragement and support for drug policy research.

In particular, we thank Kasia Malinowska, Director of the Global Drug Policy Programme at Open Society Foundations, without whom this would not have been possible. We dedicate this book to Kasia, and acknowledge the immense contribution that she has made in supporting voices, perspectives and ideas North and South of the globe that would have otherwise struggled to overcome prejudice, hostility and lack of funding opportunities available for this vitally important but marginalised issue area. Dziękujemy Ci. Z wyrazami miłości.